Next-generation sequencing of the whole MEFV gene in Japanese patients with familial Mediterranean fever: a case-control association study.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 25 09 2019
accepted: 02 05 2020
pubmed: 8 10 2020
medline: 19 12 2020
entrez: 7 10 2020
Statut: ppublish

Résumé

We aimed to identify the whole nucleotide sequence of the Mediterranean fever (MEFV) gene in familial Mediterranean fever (FMF) and reveal novel single nucleotide variants (SNVs) associated with the susceptibility of FMF. SeqCap capturing technique followed by Illumina next-generation sequencing have been used to assess two hundred SNVs in the whole region of MEFV in 266 Japanese patients with FMF and 288 ethnically matched controls. We performed an association analysis using these SNVs to identify genetic variants that predispose to FMF. We identified the two most significant SNVs [rs28940578; M694I in exon 10, odds ratio (OR) = 153, p=2.47×10-21 and rs3743930; E148Q in exon 2, OR = 1.65, p<0.0005]. Stratified analysis identified rs28940578 as a risk allele in typical FMF. Haplotype AG, defined by rs401298 and rs28940578, was the most significant and prevalent among patients with typical FMF compared with controls (22.4% vs. 0%, respectively; OR = 137, p=1.44×10-31). Haplotype GTC, defined by rs11466018, rs224231, and rs401877, was the most significant among patients with typical FMF without the rs28940578 mutation compared with controls (15.9% vs. 6%, respectively; OR = 12.4, p=0.004). rs28940578 is associated with the highest risk in typical FMF cases. This is consistent with results from previous studies in Japan. We found a novel MEFV gene haplotype that confers susceptibility of FMF among typical FMF without the rs28940578 mutation. There were no relevant SNVs identified in MEFV among the atypical FMF group.

Identifiants

pubmed: 33025889
pii: 14807

Substances chimiques

MEFV protein, human 0
Pyrin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-41

Auteurs

Tomohiro Koga (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences; and Centre for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan. tkoga@nagasaki-u.ac.jp.

Shuntaro Sato (S)

Nagasaki University Hospital, Clinical Research Centre, Japan.

Hiroyuki Mishima (H)

Department of Human Genetics, Nagasaki University Atomic Bomb Disease Institute, Japan.

Kiyoshi Migita (K)

Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Yushiro Endo (Y)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Masataka Umeda (M)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Remi Sumiyoshi (R)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Fumiaki Nonaka (F)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences; and Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan.

Shoichi Fukui (S)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Shin-Ya Kawashiri (SY)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Naoki Iwamoto (N)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Kunihiro Ichinose (K)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Mami Tamai (M)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Hideki Nakamura (H)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Tomoki Origuchi (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Yukitaka Ueki (Y)

Centre for Rheumatic Disease, Sasebo Chuo Hospital, Sasebo, Japan.

Junya Masumoto (J)

Department of Pathology, Ehime University Graduate School of Medicine and Proteo-Science Centre, Toon, Ehime, Japan.

Kazunaga Agematsu (K)

Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Matsumoto, Japan.

Akihiro Yachie (A)

Department of Paediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan.

Koh-Ichiro Yoshiura (KI)

Department of Human Genetics, Nagasaki University Atomic Bomb Disease Institute, Japan.

Katsumi Eguchi (K)

Centre for Rheumatic Disease, Sasebo Chuo Hospital, Sasebo, Japan.

Atsushi Kawakami (A)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH